Loading…
Loading…
MediPharm Labs Corp. (LABS:CA) Q2 2026 Earnings Call Transcript
Q2 2026 Adjusted EBITDA1 of $0.9M, the Company's strongest quarterly performance since 20192 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 Net Revenue of $10.0M, an increase of 11% versus Q1 2026 with German revenue increasing 45% sequentially and 33% year over year Cash of $9.9M consistent with Q1 2026, and the Company remains virtually debt free, with outright ownership of two production facilities appraised at over $15M Positive Phase II LiBBY trial results presented demonstrating statistically significant improvement in agitation symptoms using MediPharm's proprietary cannabinoid formulation Management to Host Conference Call / Webcast on August 13th, 2026, at 10:00 am ET TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2026 ("Q2 2026"). The Company improved sequentially on revenue, gross margin and Adjusted EBITDA versus the three months ended March 31, 2026 ("Q1 2026").
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three and six months ended June 30th, 2026, before markets open on Thursday, August 13th, 2026.
TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life's End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company's proprietary oral cannabinoid formulation for the treatment of agitation in patients with advanced dementia. The results were presented by the LiBBY team at AAIC in London, United Kingdom on July 14, 2026.
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares (“Shareholders”) held today. There were 389 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 130,357,074 common shares, representing 30.68% of MediPharm's total issued and outstanding common shares as of the record date for the Meeting.
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the "Meeting") of holders of common shares ("Shareholders") held today.
Annual and Special Meeting to be held virtually on Wednesday, June 17, 2026 at 11:00 a.m. (Eastern Time).
MediPharm Labs Corp. (LABS:CA) Q1 2026 Earnings Call Transcript
No recent filings indexed.